Your browser doesn't support javascript.
loading
Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer.
Kerzeli, Iliana K; Kostakis, Alexandros; Türker, Polat; Malmström, Per-Uno; Hemdan, Tammer; Mezheyeuski, Artur; Ward, Douglas G; Bryan, Richard T; Segersten, Ulrika; Lord, Martin; Mangsbo, Sara M.
Afiliación
  • Kerzeli IK; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Kostakis A; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Türker P; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
  • Malmström PU; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
  • Hemdan T; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
  • Mezheyeuski A; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
  • Ward DG; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Bryan RT; Bladder Cancer Research Centre, Institute of Cancer & Genomic Sciences, College of Medical & Dental Sciences, University of Birmingham, Birmingham, UK.
  • Segersten U; Bladder Cancer Research Centre, Institute of Cancer & Genomic Sciences, College of Medical & Dental Sciences, University of Birmingham, Birmingham, UK.
  • Lord M; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
  • Mangsbo SM; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
BMC Cancer ; 23(1): 605, 2023 Jun 30.
Article en En | MEDLINE | ID: mdl-37391708
ABSTRACT

BACKGROUND:

Urothelial bladder cancer is most frequently diagnosed at the non-muscle-invasive stage (NMIBC). However, recurrences and interventions for intermediate and high-risk NMIBC patients impact the quality of life. Biomarkers for patient stratification could help to avoid unnecessary interventions whilst indicating aggressive measures when required.

METHODS:

In this study, immuno-oncology focused, multiplexed proximity extension assays were utilised to analyse plasma (n = 90) and urine (n = 40) samples from 90 newly-diagnosed and treatment-naïve bladder cancer patients. Public single-cell RNA-sequencing and microarray data from patient tumour tissues and murine OH-BBN-induced urothelial carcinomas were also explored to further corroborate the proteomic findings.

RESULTS:

Plasma from muscle-invasive, urothelial bladder cancer patients displayed higher levels of MMP7 (p = 0.028) and CCL23 (p = 0.03) compared to NMIBC patients, whereas urine displayed higher levels of CD27 (p = 0.044) and CD40 (p = 0.04) in the NMIBC group by two-sided Wilcoxon rank-sum tests. Random forest survival and multivariable regression analyses identified increased MMP12 plasma levels as an independent marker (p < 0.001) associated with shorter overall survival (HR = 1.8, p < 0.001, 95% CI1.3-2.5); this finding was validated in an independent patient OLINK cohort, but could not be established using a transcriptomic microarray dataset. Single-cell transcriptomics analyses indicated tumour-infiltrating macrophages as a putative source of MMP12.

CONCLUSIONS:

The measurable levels of tumour-localised, immune-cell-derived MMP12 in blood suggest MMP12 as an important biomarker that could complement histopathology-based risk stratification. As MMP12 stems from infiltrating immune cells rather than the tumor cells themselves, analyses performed on tissue biopsy material risk a biased selection of biomarkers produced by the tumour, while ignoring the surrounding microenvironment.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Carcinoma de Células Transicionales Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Carcinoma de Células Transicionales Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Suecia